Chemicals and pharmaceuticals · VIRI

Virios Therapeutics, Inc.

12 filings mentioning 6 of the compliance and risk topics we track. Every row links to the filing on EDGAR.

12filings we hold
6topics disclosed
Chemicals and pharmaceuticalsindustry
GAbased in

Across 12 filings we hold, Virios Therapeutics, Inc. has written down 6 of the topics we track. That places it 82 of 737 companies we hold in chemicals and pharmaceuticals, by how much we have collected.

VIRI Chemicals and pharmaceuticals

What this obligates

Every instrument in our corpus that governs something Virios Therapeutics, Inc. has written into a filing. Not what they said. What applies once they have said it.

ISO 27001:202242
ISO 37001:201639
ISO 3700126
DORA19
NIST SP 800-16115
COSO Internal Control9
PCAOB AS 22014
IFRS 172
NIST SP 800-161 Rev 11

9 frameworks, 157 controls between them, deduplicated across topics.

What it discloses

Tracked topics appearing in this company's filings, most frequent first.

Internal Control8
Vendor Risk Management4
Restatement2
Enforcement Action2
Consent Order1
Material Weakness1

Bars are scaled against this company's most frequent topic, not against the market. The table below has the exact counts.

TopicFilingsMost recent
Internal Control82026-01-13
Vendor Risk Management42026-03-18
Restatement22025-11-21
Enforcement Action22025-11-28
Consent Order12024-10-07
Material Weakness12024-10-07

When it filed

Filings we hold, by year. Hover a bar for the count.

22
23
24
25
26

Recent filings

FiledFormItem
2026-03-1810-Kfiling
2026-01-138-KEntry into a material agreement, Item 1.02, Item 3.02filing
2025-11-288-KEntry into a material agreement, Financial statements and exhibitsfiling
2025-11-218-KDirector or officer departure, Shareholder vote, Financial statements and exhibitsfiling
2025-09-298-KEntry into a material agreement, Item 3.02, Item 3.03filing
2025-03-3110-Kfiling
2025-03-148-KEntry into a material agreement, Other material event, Financial statements and exhibitsfiling
2024-12-188-K/AFinancial statements and exhibitsfiling
2024-10-078-KEntry into a material agreement, Completion of an acquisition, Item 3.02filing
2024-05-208-KEntry into a material agreement, Other material event, Financial statements and exhibitsfiling
2024-03-0810-K/Afiling
2024-03-0110-Kfiling

Others in chemicals and pharmaceuticals

The companies we hold most on in the same industry. Each opens side by side with this one.

CompanyFilings
OPKOPKO HEALTH, INC.12compare →
FGENFIBROGEN INC12compare →
PTNPALATIN TECHNOLOGIES INC12compare →
OTLCOncotelic Therapeutics, Inc.12compare →
NKTRNEKTAR THERAPEUTICS12compare →
APALEXION PHARMACEUTICALS, INC.12compare →
New here? Signals tracks the compliance and risk language public companies put into their SEC filings, and cross-references it against 723 frameworks and 20,473 controls. See what moved today or check how much of a framework you already cover.

What this page is

Every row comes from SEC full-text search over this company's filings, matched against the compliance and risk phrases we track. It is a record of what the company itself wrote down in documents it is legally accountable for. It is not an assessment of the company, a rating, or a claim about how well it manages anything.

A phrase appearing in a filing frequently means the risk section mentions it, not that an event occurred. Where an item number indicates an actual event, the Item column says so.

All of chemicals and pharmaceuticals · All companies · Today's edition